Abstract

Microvascular leak plays a critical role in the outcome of sepsis. Counteracting vascular leakage has recently raised a huge interest in the field but therapeutic targets and translation studies are crucially lacking. The inventors hypothesized that ANGPTL4 might counteract lipopolysaccharide-induced vascular hyperpermeability. Mechanistically, the inventors show that the C-terminal fragment of ANGPTL4 recapitulates full-length ANGPTL4 inhibition of vascular permeability by stabilizing endothelial cell adherent junctions whereas the N-terminus has no such effect. The inventors further demonstrate that giving human recombinant c- ANGPTL4 to mice prevents microvascular leak and mortality induced by LPS. In humans, the inventors describe the association between ANGPTL4 plasma level at time of inclusion and 90- day mortality in sepsis or septic shock patients French and European Outcome Registry in Intensive Care Units (FROG-ICU). In conclusion, the inventors demonstrate that suppressing vascular permeability by c-ANGPTL4 could be a novel therapeutic for the treatment of sepsis capillary leak syndrome. Either alone or in combination with existing drugs, c-ANGPTL4 could contribute to the reduction of mortality in patients with shock states.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers

Abstract

opt12iNN) within a detection zone (100) surrounding the mobile device (D), and a control system (30) configured to impose, on the mobile device (D), a modified trajectory (T') enabling it to reach the target position. The modified trajectory is dependent on the optimal trajectory and on the position of each intruding mobile device at each instant t during movement.

IPC Classes  ?

• G05D 1/242 - Means based on the reflection of waves generated by the vehicle
• G05D 1/633 - Dynamic obstacles
• G08G 5/80 - Anti-collision systems

Abstract

The present disclosure concerns an ultrasound 3D imaging probe (200) for imaging vascular activity dynamically at a microscopic scale in an organ of a body of a living being, the probe (200) comprising : - a mosaic ultrasound array (100) comprising a plurality of polygonal transducer element pads, each pad (101) comprising a set of transducer elements (102) distributed on a substrate (103), each transducer element (102) being configured to acquire at least a backscattered ultrasound wave from the organ following an ultrasound emission in said organ; - a support frame (10) comprising an intern surface intended to be placed facing said body; - each polygonal transducer element pad (101) being located and attached in a removable manner on said internal surface of the support frame (10).

IPC Classes  ?

• A61B 8/08 - Clinical applications
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves

Abstract

The invention relates to novel monoclonal antibodies that bind to human interferon-alpha 2 (IFN-α2) and human interferon-omega 1 (IFN-ω1), two subtypes of type I interferons that play important roles in innate and adaptive immunity. Some of the antibodies are capable of neutralizing the biological activity of both IFN-α2 and IFN-ω1. The antibodies can be used for the treatment of various diseases and conditions that are associated with excessive or dysregulated production of type I interferons, such as autoimmune diseases, inflammatory diseases. The antibodies can also be used for the diagnosis of these diseases and conditions by detecting the presence or level of IFN-α2 and IFN-ω1 in biological samples. The invention further provides methods of producing the antibodies, nucleic acids encoding the antibodies, and pharmaceutical compositions comprising the antibodies.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to a cyclodextrin derivative which comprises: - glycosidic subunits of chemical structure (4): (4), - optionally at least one glycosidic subunit of chemical structure (5): (5), the total number of glycosidic subunits of chemical structure (4) and chemical structure (5) being equal to an integer n of between 5 and 30, and at least 2 x of the x of the glycosidic subunits of chemical structure (4) being different from one another. The invention relates to a process for producing the CD derivative and to the applications thereof.

IPC Classes  ?

• C08B 37/16 - CyclodextrinDerivatives thereof
• C08L 5/16 - CyclodextrinDerivatives thereof
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds

Abstract

The invention relates to a contrast agent which comprises a gadolinium compound in an effective amount, the gadolinium compound comprising a complexing group in the form of an N-hydroxylamine, which can be protonated or deprotonated as a function of the pH, and another complexing group in the form of an imine (preferably a pyridine). Preferred gadolinium compounds are the compounds of chemical structures (A) and (B): The invention also relates to a method for acquiring medical-imaging images which involves the administration of the contrast agent, and to the use thereof in the diagnosis of tissue acidosis.

IPC Classes  ?

• A61K 49/08 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by the carrier
• A61K 49/10 - Organic compounds
• C07D 257/00 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms

Abstract

Inventors have firstly demonstrated that the transcriptomic signature of PTENpc-/-medmed cells is enriched in human MSPC signature, associated to metastases and ADT resistance. Using scRNAseq specifically with sorted PTENpc-/-LSCmedcells, they identified three distinct LSCmedclusters and showed that castration favors the emergence of the most stem-like LSCmedsubpopulation by cell plasticity. In the latter, they identified the transcription factor FOSL1/AP-1 and the kinase PIM1 as relevant therapeutic targets, and they showed that combined inhibition using JQ1, a BET/AP-1 inhibitor, and CX-6258, a pan-PIM kinase inhibitor, efficiently prevents PTENpc/-LSCmedcell growth in organoids. These findings were confirmed in the human prostate HPV10 cell line here identified as a robust model of Club/Hillock cells. Combined drug delivery to castrated PTEN-null mice induced a significant prostate weight decrease associated with the reduction of histopathological phenotypes and dramatically altered organoid-formation capacity of LSCmed cells sorted from these tumors. Accordingly, the drug combination significantly delayed tumor growth of MSPC-like human PC-3 cells subcutaneously injected into castrated immunodeficient mice. Altogether, this work shows a new therapeutic potential of combined FOSL1 and PIM1 targeting to prevent, or at least delay, the growth of MSPC-like cells. Accordingly, the invention relates to i) an inhibitor of FOSL1 and ii) an inhibitor of PIM1, as a combined preparation for use in the treatment of prostate cancer in a subject in need thereof.

IPC Classes  ?

• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/423 - Oxazoles condensed with carbocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

An electrolyte composition for a Zinc metal electrochemical device said electrolyte composition comprising water, a zinc salt, and an additive of formula (I), its use and an electrochemical device comprising said electrolyte.

IPC Classes  ?

• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 4/24 - Electrodes for alkaline accumulators
• H01M 10/36 - Accumulators not provided for in groups

Abstract

22 electrochemical device said electrolyte composition comprising water, a zinc salt, and a combination of additives, wherein the combination of additives comprises an organic additive and an additive of formula (I), its use and an electrochemical device comprising said electrolyte.

IPC Classes  ?

• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/36 - Accumulators not provided for in groups

Abstract

The present disclosure proposes a method and apparatus for imaging at a microscopic scale a region of an organ of a human or animal, allowing the use of a 2D subsampled ultrasound probe while providing 3D ULM images with high resolution usually obtained only with a full 2D array matrix, by sorting the detected microbubbles and keeping only the microbubbles corresponding to the spots belonging to the main lobe of the Point Spread Function (PSF) of the microbubble and removing the phantom microbubbles corresponding to the spots belonging to the side lobes. It is also possible to provide a 3D non-invasive imaging of the microvascular flow of the region of an organ, such as a brain in-vivo, with high resolution and high sensitivity.

IPC Classes  ?

• A61B 8/08 - Clinical applications
• G01S 15/89 - Sonar systems specially adapted for specific applications for mapping or imaging

Abstract

The invention relates to novel monoclonal antibodies that bind to human interferon-alpha 2 (IFN-α2), one subtype of type I interferons that play important roles in innate and adaptive immunity. Some of the antibodies are capable of neutralizing the biological activity of both IFN-α2. The antibodies can be used for the treatment of various diseases and conditions that are associated with excessive or dysregulated production of type I interferons, such as autoimmune diseases, inflammatory diseases. The antibodies can also be used for the diagnosis of these diseases and conditions by detecting the presence or level of IFN-α2 in biological samples. The invention further provides methods of producing the antibodies, nucleic acids encoding the antibodies, and pharmaceutical compositions comprising the antibodies.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to novel monoclonal antibodies that bind to human interferon-alpha 2 (IFN-α2), one subtype of type I interferons that play important roles in innate and adaptive immunity. Some of the antibodies are capable of neutralizing the biological activity of both IFN-α2. The antibodies can be used for the treatment of various diseases and conditions that are associated with excessive or dysregulated production of type I interferons, such as autoimmune diseases, inflammatory diseases. The antibodies can also be used for the diagnosis of these diseases and conditions by detecting the presence or level of IFN-α2 in biological samples. The invention further provides methods of producing the antibodies, nucleic acids encoding the antibodies, and pharmaceutical compositions comprising the antibodies.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/56 - IFN-alpha
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to novel monoclonal antibodies that bind to human interferon-omega 1 (IFN-ω1), one subtype of type I interferons that play important roles in innate and adaptive immunity. The antibodies can also be used for the diagnosis of auto-immune diseases and viral infections by detecting the presence or level of IFN-ω1 in biological samples. The invention further provides methods of producing the antibodies, nucleic acids encoding the antibodies, and pharmaceutical compositions comprising the antibodies.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to bromotyrosine derivatives compounds for use in treating protein misfolding diseases.

IPC Classes  ?

• A61K 31/69 - Boron compounds
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

uimxxS cc mm) at every point of spatial position (x, z); g) construction of an image from the dynamic confocal signals.

IPC Classes  ?

• G01S 7/52 - Details of systems according to groups , , of systems according to group
• G01N 29/44 - Processing the detected response signal
• G01S 15/89 - Sonar systems specially adapted for specific applications for mapping or imaging

Abstract

ui ξξξξ ω ξξξξ ω xxxx M ξξξξ ωx xxxx MM). The spatio-frequential basis ξ ensures an independence between the spatial and sequential data and makes it possible to demonstrate a chromato-angular memory effect associated with the field reflected by the object. The scattering screen makes it possible to increase the base resolution of the acquisition probe.

IPC Classes  ?

• G01S 7/52 - Details of systems according to groups , , of systems according to group
• G01N 29/44 - Processing the detected response signal
• G01S 15/89 - Sonar systems specially adapted for specific applications for mapping or imaging
• A61B 8/08 - Clinical applications

Abstract

The present invention relates to a method of screening for a molecule mimicking interleukin 34 (IL-34) bone regulation activity based on the binding of IL-34 to bone morphogenetic proteins (BMPs), which comprises the steps of: 1) reacting a candidate molecule and BMPs under suitable conditions, 2) detecting the binding of the candidate molecule to BMPs and optionally a bone regulation activity, 3) comparing the binding and optionally the bone regulation activity detected in step 2) to a control, and 4) selecting a molecule capable of binding to BMPs and inducing osteoblast differentiation and activities without activating osteoclast functions. The present invention also relates to a molecule mimicking IL-34 bone regulation activity based on the binding of IL-34 to BMPs, obtained by the method, and to a pharmaceutical composition comprising the molecule and a pharmaceutically acceptable carrier.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to an electric power supply system configured to output a voltage from a capacitor arm comprising 6+2n capacitors. Each capacitor of rank i has a first terminal forming a terminal of rank i of the capacitor arm, and a second terminal forming a terminal of rank i+1 of the capacitor arm, i being a natural number between 1 and 6+2n. The power supply system furthermore comprises: for each capacitor of rank i, i ranging from 2 to 6+2n-1, a respective generic module, each generic module comprising a switch arm the ends of which are connected to the terminals of the capacitor of rank i, a branch comprising a DC voltage source and an inductor in series, a first end of the branch being connected to the centre tap of the switch arm; a first and second terminating module, each comprising a voltage source, a first switch arm and a second switch arm, the centre taps of the first and second arms being connected to a first, respectively second, branch comprising a respective inductor. Terminals of the first terminating module are connected to the terminals of rank 1, 2, 3 of the capacitor arm. Terminals of the second terminating module are connected to the terminals of rank 6+2n-1, 6+2n, 6+2n+1 of the capacitor arm. Second ends of the branches of the generic modules are connected and the switch arms are controlled such that the currents passing through the terminals of the capacitor arm are balanced.

IPC Classes  ?

• H02M 1/00 - Details of apparatus for conversion
• H02M 3/158 - Conversion of DC power input into DC power output without intermediate conversion into AC by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only with automatic control of output voltage or current, e.g. switching regulators including plural semiconductor devices as final control devices for a single load

Abstract

The present invention relates to a method for producing 1-chloro-2,2-difluoroethane (HCFC-142 or F142), by reacting gaseous 1,1,2-trichloroethane (HCC-140 or T112) and/or 1,2-dichloroethylene (HCO-1130-E or 1,2-DCE) with gaseous anhydrous hydrogen fluoride (HF), in a reactor in the presence of nanodiamonds, which is economically feasible at industrial scale and which provides high yield and selectivity.

IPC Classes  ?

• C07C 17/20 - Preparation of halogenated hydrocarbons by replacement by halogens of halogen atoms by other halogen atoms
• C07C 19/12 - Acyclic saturated compounds containing halogen atoms containing fluorine and chlorine having two carbon atoms

Abstract

The present invention relates to the treatment of the COVID-19, here, the inventors generated potent non-neutralizing pan-SARS-CoV-2 mAb, notably the antibody C10, targeting a conserved region of the virus. Noteworthy, C10 demonstrated remarkable efficacy in recognizing nearly all known variants of the virus and effectively binding infected cells. Leveraging this pan-SARS-CoV-2 mAb, they have engineered CAR-T cells capable of efficiently killing lung epithelial cells infected with the virus. Overall, their work identifies a pan-SARS-Cov-2 able to target bona fide infected cells and provides a proof-of-concept for the potential use of CAR-T cell therapy in combating SARS-CoV-2 infections. Their findings also highlight the potential of non-neutralizing mAbs in mediating immune protection against emerging infectious diseases. Thus, the present invention relates to anti-spike antibodies, particularly in a purified form or in an isolated form and their use to treat SARS-CoV-2. Particularly, the present invention is defined by the claims.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses
• A61K 40/31 - Chimeric antigen receptors [CAR]

Abstract

iiiiiiii111112122 are selected from F, Cl, Br, S, O or I.

IPC Classes  ?

• C09K 5/16 - Materials undergoing chemical reactions when used

Abstract

Herein disclosed are compounds of formula (I), which are metabolized into, or act as, analogues of oncosterone (6-oxo-cholestan-3β,5α-diol), a metabolite produced by tumor cells overexpressing cholesterol-5,6-epoxide hydrolase (ChEH) and/or expressing 11β-hydroxysteroid dehydrogenase type 2 (HSD2) and the glucocorticoid receptor (GR), neutralizing the signaling pathway and tumorigenicity of oncosterone. The compounds of formula (I) herein disclosed are thus useful in preventing and/or treating cancers, in subjects, preferably humans, overexpressing cholesterol-5,6-epoxide hydrolase (ChEH) and/or expressing 11β-hydroxysteroid dehydrogenase type 2 (HSD2) and the glucocorticoid receptor (GR). In addition, being analogues of oncosterone, some of the compounds of formula (I) are also useful in the prevention and/or treatment of cancers expressing the glucocorticoid receptor (GR).

Abstract

The present invention pertains to the provision of conjugates for the detection of target molecules by using mass spectrometry imaging. In particular, disclosed herein a particularly innovative conjugate for the detection of target molecules that is usable in the four following techniques of MSI: MALDI-MSI, DESI-MSI, nano-DESI- MSI and SpiderMass (MSI).

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C07D 403/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The invention relates to a system (101) for measuring a photoinduced deformation of a sample, the system comprising a Michelson interferometer (103), wherein the Michelson interferometer comprises a first light source and means for acquiring and converting the optical interference signal into an electrical signal, a second light source (201), an arbitrary signal generator (205) configured to modulate the brightness of the second light source (201) at a frequency, and a signal-processing unit (211) for processing the electrical signal. The second beam (203) illuminates the sample, and the processing unit (211) is configured to determine the amplitude of the deformation of the sample from the electrical signal.

IPC Classes  ?

• G01B 11/16 - Measuring arrangements characterised by the use of optical techniques for measuring the deformation in a solid, e.g. optical strain gauge
• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated

Abstract

The invention relates to a method for preparing a multilayer semiconductor system, the method comprising the following steps: (a) depositing, on a monocrystalline substrate, a thin layer that comprises a material comprising at least one element from column IIIB and elements from column VB, referred to as IIIB-VB materials, which material is epitaxied; (b) depositing, on the thin layer comprising the IIIB-VB material, a metal source of a d-block transition metal, preferably under a chalcogen gas atmosphere, wherein the chalcogen is preferably not oxygen and is preferably sulphur; and wherein the metal source of the d-block transition metal preferably comprises more than 99.9% of the transition metal expressed as a percentage by weight relative to the total weight of the metal source.

IPC Classes  ?

• C30B 23/02 - Epitaxial-layer growth
• C30B 25/18 - Epitaxial-layer growth characterised by the substrate
• C30B 29/46 - Sulfur-, selenium- or tellurium-containing compounds
• C30B 33/02 - Heat treatment

Abstract

According to one aspect, the present description relates to a system (100) for detecting the seatbelt-wearing state of at least one passenger of at least one first vehicle (301), the system comprising detection means configured to acquire, according to a linear and/or circular polarisation, at least one first polarised image of a field of view of the first vehicle, consisting of a plurality of pixels, and determining at least one enriched image with n channels of the field of view of the first vehicle, n ≥ 1, wherein the enriched image consists of a plurality of pixels comprising n values, at least one of which values is a polarisation value determined from pixel values of the at least one first polarised image. The system further determines, from the at least one enriched image, a seatbelt-wearing state of the at least one passenger of the first vehicle.

IPC Classes  ?

• G06V 10/147 - Details of sensors, e.g. sensor lenses
• B60N 2/00 - Seats specially adapted for vehiclesArrangement or mounting of seats in vehicles
• B60R 21/00 - Arrangements or fittings on vehicles for protecting or preventing injuries to occupants or pedestrians in case of accidents or other traffic risks
• B60R 22/48 - Control systems, alarms, or interlock systems, for the correct application of the belt or harness
• G06V 20/56 - Context or environment of the image exterior to a vehicle by using sensors mounted on the vehicle
• G08G 1/00 - Traffic control systems for road vehicles
• G08G 1/01 - Detecting movement of traffic to be counted or controlled
• G08G 1/04 - Detecting movement of traffic to be counted or controlled using optical or ultrasonic detectors

Abstract

The invention relates to an electric power supply system configured to deliver a DC voltage from a first end and a second end of a capacitor arm. The capacitor arm has 4+2n capacitors, n being a natural number, each capacitor being connected to the ends of a respective switch arm. The power supply system is such that, from the first end of the capacitor arm to the second end of the capacitor arm, i being a natural number between 1 and 4+2n: wherein for first capacitors of rank i=2 or i=4+2n-1, respectively, the midpoint of the corresponding switch arm is connected to a first branch comprising a first DC voltage source configured to deliver a voltage having a first value V and a first inductor in series, the first branch additionally being connected to the first end of the capacitor arm or to the second end of the capacitor arm, respectively; and wherein for second capacitors of odd rank i different from 4+2n-1, the midpoint of the switch arm corresponding to the capacitor of rank i and the midpoint of the switch arm corresponding to the capacitor of rank i+3 are connected by a second branch comprising a second DC voltage source configured to deliver a voltage having a value 2 x V and a second inductor in series.

IPC Classes  ?

• H02M 1/00 - Details of apparatus for conversion
• H02M 3/158 - Conversion of DC power input into DC power output without intermediate conversion into AC by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only with automatic control of output voltage or current, e.g. switching regulators including plural semiconductor devices as final control devices for a single load

Abstract

The present invention relates to a method for preparing a fluoropyridine that comprises fluorinating a halopyridine with hydrogen fluoride in the gas phase and in the presence of nanodiamonds, at least part of the surface of which contains sp2 carbon atoms and hydrogenated and/or oxygenated surface functions, such that there is formed a compound of formula (I) and an acid chosen from HCl, HBr and a mixture thereof.

IPC Classes  ?

• C07D 213/61 - Halogen atoms or nitro radicals

Abstract

The invention relates to a device (1) for the detection of spin waves, comprising - a magnetic film (2) adapted to guide a spin wave excited by an excitation means (5), - a magneto-resistive element (3), wherein the magneto-resistive element (3) is coupled to the magnetic film (2) by magnetic coupling, wherein the magneto-resistive element (3) is configured to exhibit a magneto-resistive effect in response to a magnetization state of the magnetic film (2), the magnetization state of at least a part of the magneto-resistive element (3) varying as a function of the guided spin wave, the device (1) further comprising: - measurement means (6) configured to detect an electrical signal corresponding to the magneto-resistive effect The invention also relates to a method for the detection of spin waves.

IPC Classes  ?

• G01R 33/09 - Magneto-resistive devices
• G01R 33/12 - Measuring magnetic properties of articles or specimens of solids or fluids
• H01F 10/32 - Spin-exchange-coupled multilayers, e.g. nanostructured superlattices
• B82Y 25/00 - Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance

Abstract

The present invention relates to a measurement circuit (16) of a stabilizer of a quantum error correction code for logical qubits, each logical qubit comprising one or several qubits being encoded in neutral atoms with interactions mediated by Rydberg states, the stabilizer being measured on one ancilla qubit and several data qubits, the measurement circuit (16) comprising, for each data qubit, a device (18) comprising a coupling unit (20) adapted to apply a laser pulse symmetrically on both the data qubit and the ancilla qubit, the laser pulse having an amplitude and a phase chosen to have a probability of occurrence of the Rydberg hopping inferior to 0.4 when both qubits are excited by said laser pulse.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G06N 10/70 - Quantum error correction, detection or prevention, e.g. surface codes or magic state distillation
• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers

Abstract

Despite the high prevalence and serious clinical implications of metabolic associated steatohepatitis (MASH) in patients with type 2 diabetes (T2D), MASH is usually overlooked in clinical practice, due to the lack of accurate biomarkers. The inventors evaluated the ability of plasma large extracellular vesicles (lEVs) to serve as noninvasive biomarkers for the diagnosis of MASH, in particular in T2D patients. Proteomic analysis identified Transferrinreceptor on lEVs (TFRC-lEVs) as associated with MASH. The inventors thus measured TFRC- lEVs on plasma samples from patients included in the derivation cohort. The proportion of patients with TFRC-lEVs concentration > 61 ng/mL was significantly higher in patients with MASH than in those with steatosis. TFRC-lEVs > 61 ng/mL remained associated with MASH after adjustment on either usual laboratory variables, or on the NASH-Test or on the Fibroscan FAST-score. When combining TFRC-lEVs with available methods the population suspected of having MASH was 32% and 29%, versus 22% and 16% for NASH-test or FAST score alone, without decreasing specificity. In conclusion, TFRC-lEVs, a marker of hepatocyte ballooning, is a promising biomarker for MASH. It could be used for patients' screening to enlarge recruitment of patients with MASH in clinical trials.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention pertains to the provision of conjugates for the detection of target molecules using mass spectrometry imaging (MSI).

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C07D 403/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to an orthopaedic screw (1) for the sacroiliac joint (71), the screw comprising a core (2) extending between a distal end (1a) and a proximal end (1b), and a first thread (3), wherein the core (1) comprises a central conical portion (21) having a first slope (α1), a distal portion (20) having a second slope (α2) smaller than the first slope (α1), and a proximal portion (22) having a third slope (α3) smaller than the first slope (α1), and wherein the first thread (3) has a height (D) that increases from the proximal end (21b) towards the distal end (21a) of the central conical portion (21), over a retaining portion (210) of the central conical portion (21), so as to enhance screw retention, in particular in osteoporotic bone.

IPC Classes  ?

• A61B 17/86 - Pins or screws

Abstract

The invention relates to a porous solid containing at least 90% by weight, relative to the total weight of the porous solid, of a polyurethane polyester copolymer. The invention also relates to the method for preparing the porous solid. The invention also relates to a medical implant material consisting of the porous solid and collagen, and to the method for preparing this material. The invention also relates to a medical implant made of the medical implant material. Finally, the invention relates to the use of the porous solid or of the medical implant material for the production of a medical implant.

IPC Classes  ?

• A61F 2/02 - Prostheses implantable into the body
• A61F 2/30 - Joints
• C08G 18/10 - Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
• C08G 18/42 - Polycondensates having carboxylic or carbonic ester groups in the main chain
• C08G 18/73 - Polyisocyanates or polyisothiocyanates acyclic
• C08L 75/06 - Polyurethanes from polyesters
• C09D 175/06 - Polyurethanes from polyesters
• A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
• A61L 27/58 - Materials at least partially resorbable by the body
• A61L 27/56 - Porous or cellular materials

Abstract

The invention relates to an imager (1) comprising: - an array of spectral filters formed of a repeating pattern of spectral filters; - an array of polarisers; - an array of photosensors; and - a processing device designed so that, for each of the different spectral bands, it forms at least one image of pixels having positions in the image that correspond, respectively, to predefined positions (i, j) of a mask (M) in the array of photosensors, wherein each of the pixels is calculated on the basis of the brightnesses measured by the photosensors for the stated spectral band contained in the mask (M) at the position (i, j) of the pixel. The pattern of spectral filters is designed such that, for each of the different spectral bands and for all of the predefined positions (i, j) of the mask (M), the photosensors for the stated spectral band have an isobarycentre located in a central virtual box (PVC) of the mask (M) having the same size as the boxes of the array of photosensors, and each of the predefined positions (i, j) of the mask (M) is offset from another predefined position (i, j) by a column or row of the array of photosensors.

IPC Classes  ?

• G01C 21/02 - NavigationNavigational instruments not provided for in groups by astronomical means
• G02B 5/20 - Filters
• G01J 4/04 - Polarimeters using electric detection means
• G01C 11/02 - Picture-taking arrangements specially adapted for photogrammetry or photographic surveying, e.g. controlling overlapping of pictures
• G01J 3/02 - SpectrometrySpectrophotometryMonochromatorsMeasuring colours Details
• G01J 3/28 - Investigating the spectrum

Abstract

The present invention relates to a technique for compensating for the non-linear distortion of an electroacoustic transducer (T) based on a post-processing operation applied to the electrical signal delivered by the transducer by means of a non-linearizing harmonic component (M) arranged downstream of same.

IPC Classes  ?

• H04R 19/00 - Electrostatic transducers

Abstract

The present invention relates to the field of the treatment of cancer. In this study, the inventors found that VDAC2 is heterogeneously expressed in MM cells. VDAC2 protein expression correlated with BAK but not with BAX protein levels. Transient silencing of VDAC2, but not VDAC1 or VDAC3, sensitized MM cells to intrinsic mitochondrial apoptosis signals, alongside with the induction of pre-activated BAK and the increase of global, MCL1 and BCL2 mitochondrial priming. They also found a that a VDAC2 compound, efesevin recapitulated the sensitization effect of VDAC2 knock-down on BH3 mimetics apoptotic response. This novel VDAC2 modulator sensitized MM cells to BH3 mimetics targeting MCL1 (S63845) or BCL2 (Venetoclax) without modifying BAK or BAX protein expression. The efficiency of the VDAC2 modulator was directly correlated with the levels of VDAC2 protein. To better understand the VDAC2/BAK interplay, The inventors generated VDAC2 KO myeloma cells. VDAC2 KO cells exhibited an important decrease of BAK protein expression while BAX remained unchanged. Accordingly, VDAC2 KO cells completely lost their mitochondrial priming. Interestingly, they also found that BAK KO myeloma cells displayed decreased levels of VDAC2. The reciprocal regulation between VDAC2 and BAK was dependent on both the proteasome and lysosome degradation pathways. Thus, the present invention relates to a combination of a VDAC2 modulator and a BH3- mimetics compound for use in the treatment of a cancer in a subject in need thereof.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to methods and pharmaceutical composition for the treatment of estrogen-dependent cancers, particularly estrogen receptor-related cancers such as estrogen receptor-positive (ER+) cancers, like ER+ breast cancer (ER+BC). The invention relates to the combined use of an inhibitor of the methyltransferase-like protein 3 (METTL3) and an inhibitor of the nuclear DNA topoisomerase I (TOP1) for the treatment of estrogen-dependent cancers, particularly estrogen receptor-related cancers such as ER+ cancers. The inhibition of METTL3 increases the sensitivity of ER + breast cancer cells to Topoisomerase-1 inhibitor.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a process for preparing a metal-organic framework (MOF) comprising a step of synthesizing the metal-organic framework (MOF) which comprises bringing at least one aluminum alkoxide into contact with at least one at least bidentate organic ligand in the presence of an aqueous solvent, whereby a colloidal suspension comprising said MOF and also an alcohol is obtained, and a step of recovering the synthesized MOF.

IPC Classes  ?

• C07F 5/06 - Aluminium compounds
• B01J 20/30 - Processes for preparing, regenerating or reactivating
• B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material

Abstract

The invention relates to a process for preparing a metal-organic framework (MOF) comprising a step of synthesizing the metal-organic framework (MOF) which comprises bringing at least one aluminum alkoxide into contact with at least one at least bidentate organic ligand in the presence of an aqueous solvent, whereby a colloidal suspension comprising said MOF and also an alcohol is obtained, and a step of coating a support with said colloidal suspension, whereby a thin layer of said MOF is deposited on said support.

IPC Classes  ?

• C07F 5/06 - Aluminium compounds
• B01J 20/30 - Processes for preparing, regenerating or reactivating

Abstract

The present invention concerns the treatment of Fibrotic interstitial lung diseases (Fibrotic ILDs) and particularly Progressive pulmonary fibrosis (PPF) such as idiopathic lung fibrosis (IPF). In particular inventors develop antisense oligonucleotides targeting HSPB5 and study their effects on the development of experimental pulmonary fibrosis. Specific antisense oligonucleotides (ASO) were designed and screened in vitro, based on their ability to inhibit both human and murine HSPB5 expression. One of them, ASO22, was selected by its capacity to inhibit TGF-β1-induced expression of HSPB5 and additional key markers of fibrosis such as PAI-1, collagen, fibronectin and α-SMA in fibroblastic human CCD-19Lu cells as well as PAI- 1 and α-SMA in pulmonary epithelial A549 cells. Intra-tracheal or intravenous administration of ASO22 in bleomycin-induced pulmonary fibrotic mice decreased HSPB5 expression and reduced fibrosis as measured by the decrease in pulmonary remodeling, collagen accumulation and Acta2 and Col1a1 expression. Altogether, these results suggest a real interest of using an antisense oligonucleotide strategy targeting HSPB5 for the treatment of pulmonary fibrosis.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides

Abstract

The present application relates to a method of treating a respiratory viral infection in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that depletes plasmacytoid dendritic cells. Another object of the present application relates to a kit of part comprising said agent and at least one further therapeutic agent as a combined preparation for simultaneous, separate or sequential use in the treatment of a respiratory viral infection in a subject in need thereof.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

The invention relates to an imaging optical system (11), comprising a primary mirror (M1), a secondary mirror (M2), a tertiary mirror (M3), and an exit pupil (PS). Light rays (21, 22, 23) originating from a scene are consecutively reflected by these three mirrors in the direction of the exit pupil. A light ray (21, 22, 23) from the scene is thus split into an initial segment (210, 220, 230), a first intermediate segment (211, 221, 231), a second intermediate segment (212, 222, 232), and a terminal segment (213, 223, 233). M1 and M2 are oriented such that the second intermediate segment (232) of a parabasal ray (23) of the system intersects the initial segment (230) of the parabasal ray. M2 and M3 are oriented such that the first intermediate segment (231) of the parabasal ray of the system intersects the terminal segment (233) of the parabasal ray. An intermediate image plane (PI) is located between M1 and M2 or between M2 and M3.

IPC Classes  ?

• G02B 17/06 - Catoptric systems, e.g. image erecting and reversing system using mirrors only
• G02B 23/06 - Telescopes, e.g. binocularsPeriscopesInstruments for viewing the inside of hollow bodiesViewfindersOptical aiming or sighting devices involving prisms or mirrors having a focusing action, e.g. parabolic mirror

Abstract

The present invention relates to an electromediated process for separating at least one first-row transition metal M1, such as nickel, from a liquid sample. The liquid sample preferably originates from a battery. The invention further relates to an electromediated process for regenerating copper and/or a primary amine from a complex comprising copper and said primary amine, an electromediated process for stripping a metal ion from a complex comprising said metal and a primary amine and an electromediated process for recovering at least one first-row transition metal M1 and/or at least one primary amine from a complex comprising said metal and said primary amine.

IPC Classes  ?

• C22B 3/42 - Treatment or purification of solutions, e.g. obtained by leaching by ion-exchange extraction
• C22B 3/00 - Extraction of metal compounds from ores or concentrates by wet processes
• C25C 1/08 - Electrolytic production, recovery or refining of metals by electrolysis of solutions of iron group metals, refractory metals or manganese of nickel or cobalt
• C25C 1/12 - Electrolytic production, recovery or refining of metals by electrolysis of solutions of copper
• C22B 3/06 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in inorganic acid solutions
• C22B 15/00 - Obtaining copper

Abstract

The invention relates to the first hydrolase that specifically digests the archaeal type of a peptidoglycan (PG), the major component of the cell wall of methanogens, named Talosaminidase. The enzyme consists of a signal peptide, several bacterial IG domains, a glycosyl hydrolase, several archaeal PG binding domains and a peptidase domain. The double enzymatic activity for the glycosyl hydrolase and the peptidase maximizes the lysis of archaeal cells with a cell wall of the archaeal PG-type. Engineering the enzyme by removing the signal peptide and bacterial IG domains and keeping only the archaeal PG binding, glycosyl hydrolase and peptidase made the enzyme easier to express and purify, without negatively influencing the enzymatic activity. Therefore, engineered Talosaminidase can be used to regulate populations of archaeal methanogens in the industrial, agricultural and medical settings, and consequently methane production.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61P 31/04 - Antibacterial agents
• C12N 9/50 - Proteinases
• C12N 9/52 - Proteinases derived from bacteria

Abstract

To apply the invention to treat a part made of used plastic comprising an organic filler and an inorganic filler, (A) pieces of the part to be treated are admixed with at least one water-immiscible organic solvent (S1), which is a good solvent for the plastic and is capable of solvating the organic filler and the plastic and of releasing the inorganic filler; (B) an aqueous solution of an agent for extracting the inorganic filler is added to the mixture obtained, the aqueous solution being capable of transferring the inorganic filler by liquid-liquid extraction from the mixture to the aqueous solution, the inorganic filler then being in the dissolved state in the aqueous solution; (C) the two immiscible phases obtained are collectively admixed with a water-immiscible solvent (S2) which is miscible with the solvent (S1) and is a poor solvent for the plastic and a good solvent for the organic filler, in order to precipitate, in at least one solid phase, the plastic in dispersed form, while leaving the organic filler in the mixture of solvents (S1) and (S2), constituting an organic liquid phase, and the inorganic filler remaining dissolved in the aqueous solution, constituting an aqueous phase; the solid plastic phase is recovered by solid-liquid separation; separated by their density difference, the organic filler and the inorganic filler respectively are isolated from each of the organic and aqueous phases obtained.

Abstract

The invention concerns a compound of formula (I) wherein R, R1and R2are independently selected form the group consisting of: a hydrogen atom, a halogen atom, an alkyl group, linear, cyclic or branched, saturated or unsaturated, possibly substituted, comprising from 1 to 10 carbon atoms, an acyl group comprising from 1 to 10 carbon atoms, a carboxyl group, an amido group comprising from 1 to 10 carbon atoms, and an imino group, possibly substituted by an alkyl group, linear, cyclic or branched, saturated or unsaturated, and wherein R3, R4, R5and R6 are independently selected form the group consisting of: a hydrogen atom, a halogen atom, a hydroxyl group, an alkyl group, linear, cyclic or branched, saturated or unsaturated, possibly substituted, comprising from 1 to 10 carbon atoms, an alkoxy group comprising from 1 to 10 carbon atoms, an acyl group comprising from 1 to 10 carbon atoms, a carbonate group from 1 to 10 carbon atoms, a carboxyl group, and a cyano group, for use as neuroprotectants, or in the treatment of disorders with reduced NAD metabolism.

IPC Classes  ?

• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Control tissues and different lesions of either adenomyosis or endometriosis were exposed in vitro during 24 hours either to vehicle (DMSO) or different doses of BYL719 or ST420, a PIK3CA inhibitor. Inventors observed that lesions treated with DMSO had a higher recruitment of the PIK3CA pathway compared to healthy endometrium. Importantly, both inhibitors were able to shut down the phosphorylation of AKT. They concluded that PIK3CA inhibition is a good therapeutic target for patients with endometriosis and adenomyosis. They also investigated the role of the PIK3CA pathway in myoma, another benign uterine condition. They observed that either alpelisib or ST420 were able to inhibit the pathway in myoma. They concluded that myoma demonstrate PIK3CA/AKT pathway activation with somatic mutation and are accessible to targeted treatment. Accordingly, the invention relates to method for treating uterine disease in a subject in need thereof comprising a step of administrating the subject with a therapeutically effective amount of PIK3CA inhibitor such as compound of formula (I), or a deuterated or tritiated form of the compound of formula (I), BYL719.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a method for producing a web of fibres comprising fibres of a copolymer based on the repeating unit derived from vinylidene fluoride (VDF), by electrospinning a solution of the fluorinated polymer. The invention also relates to the webs of fibres that can be obtained using said method. Lastly, the invention relates to the various applications of said webs of fibres as a filtration device for filtering air and/or liquid.

IPC Classes  ?

• B01D 39/16 - Other self-supporting filtering material of organic material, e.g. synthetic fibres
• D01D 1/02 - Preparation of spinning solutions
• D01D 5/00 - Formation of filaments, threads, or the like
• D01F 6/12 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds from polymers of halogenated hydrocarbons from polymers of fluorinated hydrocarbons
• D01F 6/32 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from copolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds comprising halogenated hydrocarbons as the major constituent
• D04H 1/728 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by electro-spinning

Abstract

Translating bacterial-based therapies to clinical success has yet been proven challenging, facing targeting inconsistencies, formulation issues and immune system noncompliance that can lead up to sepsis. To counter these limitations, the invention provides the Smart Polymer Shield (SPS) for the encapsulation of individual live cells.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to a method for configuring a system for classifying images of a target domain on the basis of a classification of images of at least one source domain, the method comprising: - encoding of pairs of texts, each pair comprising a text of the source domain and a text of the target domain, by a neural network-based encoder, previously trained and configured to encode text and image data pairs; - training a first neural network to determine parameters of a first augmentation function, this training being done by minimising a first distance D between the text of the encoded target domain and the text of the source domain of a single pair, encoded by the text encoder and augmented by the first augmentation function; - training of the classification system, the training being carried out on the images of the source domain encoded by the trained image encoder and then transformed by the first augmentation function.

IPC Classes  ?

• G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 20/70 - Labelling scene content, e.g. deriving syntactic or semantic representations

Abstract

The invention relates to a mould for manufacturing at least one marking pad for marking at least one test sample, the mould comprising a body having at least: - a base provided with a first main face and a second main face; - at least one flank extending from the base to at least partly form a peripheral edge of the base, wherein the first main face of the base thus forms a bottom of the body, at least one hundred holes extending in at least one region of the base so as to open at a first end on the first main face and to be blind at a second end opposite the first end, wherein the holes are arranged in a predetermined pattern. The invention also relates to the corresponding pad and method.

IPC Classes  ?

• B29C 33/38 - Moulds or coresDetails thereof or accessories therefor characterised by the material or the manufacturing process
• B29C 33/40 - Plastics, e.g. foam or rubber
• B29C 33/42 - Moulds or coresDetails thereof or accessories therefor characterised by the shape of the moulding surface, e.g. ribs or grooves

Abstract

The present invention relates to compositions, and in particular to pharmaceutical compositions, comprising, or even consisting of, a suspension of bacteriophages of the class Caudoviricetes, the bacteriophages having lytic activity against at least one Gram-positive bacterial strain, at a titer of at least 108 PFU/mL, in a dispersing medium comprising, or even consisting of: - at least one non-ionic surfactant, and in particular a single non-ionic surfactant, selected from the polysorbate family, at a molar concentration greater than its critical micelle concentration, but not exceeding 2 mg/mL, and/or the poloxamer family, at a concentration ranging from 0.005% (w/v) to 30% (w/v); - one or more neutral salts formed from a pair of monovalent ions, the total molar concentration of which is in the range from 75 to 160 mM; - a buffer mixture imparting to the composition a pH from 6.0 to 7.9, and preferentially from 7.0 to 7.5, typically selected from hydrogen phosphate ion/dihydrogen phosphate, citric acid/citrate ion and citric acid/hydrogen phosphate ion ion pairs, wherein the molarity of the buffer mixture is in the range from 4 mM to 100 mM; - water, wherein the composition comprises less than 0.9 bacterial endotoxin units per mL and a total protein concentration of less than 0.09 mg/mL, and wherein the bacteriophage suspension in the dispersing medium has an osmolality of between 150 mOsm/kg and 600 mOsm/kg; the invention also relates to associated methods and uses.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• A61M 3/00 - Medical syringes, e.g. enemataIrrigators
• A61P 31/04 - Antibacterial agents
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The invention relates to hybrid polymer/filler materials prepared from bipyridine derivatives functionalised with acrylate groups of formula (I) and/or metal complexes comprising said functionalised bipyridine derivatives, wherein the polymer comprising the functionalised bipyridines can form a shell around the filler, as well as to the method for preparing same and the uses thereof.

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 471/04 - Ortho-condensed systems
• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
• C08G 79/14 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon a linkage containing two or more elements other than carbon, oxygen, nitrogen, sulfur, and silicon

Abstract

mesmesmesmesmes-thmes-th, triggers (33) a measurement event (4).

IPC Classes  ?

• H04Q 9/00 - Arrangements in telecontrol or telemetry systems for selectively calling a substation from a main station, in which substation desired apparatus is selected for applying a control signal thereto or for obtaining measured values therefrom
• H04N 25/707 - Pixels for event detection

Abstract

The present invention relates to a crosslinkable two-component composition comprising: - a component A comprising: - a compound having one of the following formulae (Ia) or (Ib): - at least one (meth)acrylate compound M1; - a component B comprising at least one compound having one of the following formulae (C) or (D).

IPC Classes  ?

• C08K 5/45 - Heterocyclic compounds having sulfur in the ring
• C08K 5/50 - Phosphorus bound to carbon only
• C09J 4/00 - Adhesives based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond
• C09J 133/14 - Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur or oxygen atoms in addition to the carboxy oxygen

Abstract

Method for monitoring the operation and/or the geometry of a wind turbine in motion comprising a tower and several blades extending from a rotor hub, the method comprising: (a) acquisition with a three-dimensional acquisition apparatus of a plurality of scans representing at least partially the wind turbine; (b) segmenting the scans to identify at least portions corresponding to the blades; (c) generating a 3D representation by at least aligning and denoising the scans with respect to a common frame of reference associated with the wind turbine and compensating for relative motion between the three-dimensional acquisition apparatus and the wind turbine; (d) computing, based on the 3D representation, at least one geometric or operational parameter and/or computing at least one geometric transformation between at least one representative part of one blade and the corresponding representative part of at least one of the other blades and computing at least one wind turbine geometric or operational parameter based on the at least one computed geometric transformation.

IPC Classes  ?

• F03D 17/00 - Monitoring or testing of wind motors, e.g. diagnostics

Abstract

The present disclosure concerns sodium-phosphate niobium bronzoïds and bronzes having the following formula: Na2Nb4P2O16 and NaNb3P2O13, and their manufacture, comprising the following steps: Annealing a mixture of precursors M1; Grinding the annealed mixture M1; Pelletizing the ground mixture M1 to obtain a pellet P1; Annealing the pellet P1; wherein M1 comprises a niobium precursor, a phosphate precursor, and a sodium precursor.

IPC Classes  ?

• C01B 25/45 - Phosphates containing plural metal, or metal and ammonium
• C01G 33/00 - Compounds of niobium
• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers

Abstract

The present disclosure concerns lithium-phosphate niobium bronzoTds and bronzes having either of the following formula: Li2Nb4P2O16 or LiNb3P2O13 and the process for their manufacture, comprising the following steps: Providing a sodium-phosphate niobium bronzoid or bronze; mixing and grinding the sodium-phosphate niobium bronzoid or bronze with a Li-comprising precursor to obtain a mixture M2; pelletizing the mixture M2 to obtain a pellet P2; annealing the pellet P2; grinding the pellet to obtain a powder W2; washing and drying the powder W2.

IPC Classes  ?

• C01B 25/45 - Phosphates containing plural metal, or metal and ammonium
• C01G 33/00 - Compounds of niobium
• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers

Abstract

The present invention relates to a method for manufacturing a part (1) with improved resistance to oxidation and high-temperature corrosion, comprising at least the deposition of a non-cracked crystalline β-Yb2Si2O7 environmental barrier layer (7) on an at least partially ceramic matrix composite material (3), wherein the environmental barrier layer is deposited by chemical vapour deposition from a gas phase comprising a precursor mixture of (a) a compound A of formula SiClxHy, in which x is an integer from 1 to 4 and y is an integer from 0 to 3, with x + y = 4, and (b) elementary ytterbium or ytterbium(III) chloride, and wherein, during deposition, a temperature between 1100°C and 1300°C and a pressure of 150 mbar or less are imposed.

IPC Classes  ?

• C04B 41/00 - After-treatment of mortars, concrete, artificial stone or ceramicsTreatment of natural stone
• C04B 41/52 - Multiple coating or impregnating
• C04B 41/89 - Coating or impregnating for obtaining at least two superposed coatings having different compositions
• C23C 16/40 - Oxides
• C23C 28/04 - Coating for obtaining at least two superposed coatings either by methods not provided for in a single one of main groups , or by combinations of methods provided for in subclasses and only coatings of inorganic non-metallic material
• F01D 5/28 - Selecting particular materialsMeasures against erosion or corrosion
• C04B 111/00 - Function, property or use of the mortars, concrete or artificial stone

Abstract

2277 crystalline environmental barrier layer (7) onto an at least partially ceramic matrix composite material (3), said environmental barrier layer being deposited by chemical vapor deposition of organometallic compound(s), at an imposed temperature, during the deposition, of between 1200°C and 1400°C and an imposed pressure of less than or equal to 40 mbar.

IPC Classes  ?

• C04B 41/00 - After-treatment of mortars, concrete, artificial stone or ceramicsTreatment of natural stone
• C04B 41/52 - Multiple coating or impregnating
• C04B 41/89 - Coating or impregnating for obtaining at least two superposed coatings having different compositions
• C23C 16/40 - Oxides
• C23C 28/04 - Coating for obtaining at least two superposed coatings either by methods not provided for in a single one of main groups , or by combinations of methods provided for in subclasses and only coatings of inorganic non-metallic material
• F01D 5/28 - Selecting particular materialsMeasures against erosion or corrosion
• C04B 111/00 - Function, property or use of the mortars, concrete or artificial stone

Abstract

One aspect of the invention relates to a pulse generator (4) for generating a current pulse on an output branch (46) upon receipt of a trigger command, comprising: • a first half-bridge (431, 432) and a second half-bridge (433, 434), the latter comprising bidirectional switches; • an inductor (45) connected between the two half-bridges; and • a controller configured, according to different configurations of the half-bridges, to charge the inductor (45) and discharge it into the output branch (46).

IPC Classes  ?

• H03K 3/53 - Generators characterised by the type of circuit or by the means used for producing pulses by the use of an energy-accumulating element discharged through the load by a switching device controlled by an external signal and not incorporating positive feedback
• H03K 3/57 - Generators characterised by the type of circuit or by the means used for producing pulses by the use of an energy-accumulating element discharged through the load by a switching device controlled by an external signal and not incorporating positive feedback the switching device being a semiconductor device
• H03K 17/06 - Modifications for ensuring a fully conducting state
• H03M 1/08 - Continuously compensating for, or preventing, undesired influence of physical parameters of noise
• H03K 17/16 - Modifications for eliminating interference voltages or currents
• H03K 17/66 - Switching arrangements for passing the current in either direction at willSwitching arrangements for reversing the current at will

Abstract

Hypomelanosis of Ito is a clinical term for patients with mosaic syndromes characterized by skin hypopigmentation and developmental disorders. The genetic causes of these rare diseases remain largely unclear. Here, we report that GNA13 is a new gene that causes Hypomelanosis of Ito. We identified an identical mutation in this gene in four unrelated patients exhibiting pigmentary mosaicism. In depth functional investigations revealed that this is an activatory mutation that alters the cytoskeleton and morphology of melanocytes via a hyperactivation of the RHOA/ROCK signalling pathway. Our results also indicate that this pathology does not necessarily originate from a decreased production of melanin, but can originate from a defect in melanosome transfer to keratinocytes due to cell shape alterations. Thus, our findings suggest for the first time a mechanism by which the clinical symptoms of patients with Hypomelanosis of Ito appear, and pave the path for new therapeutic approaches. Altogether, the present invention relates to a method for treating a patient suffering from hypomelanosis of Ito by administering a ROCK inhibitor and/or RHOA inhibitor.

IPC Classes  ?

• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/38 - Heterocyclic compounds having sulfur as a ring hetero atom
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 17/00 - Drugs for dermatological disorders

Abstract

The present invention relates to a combination of at least two different resorcinol derivatives, wherein one resorcinol derivative is a 4-alkylresorcinol of formula (I), a pharmaceutically acceptable salt, and/or a solvate thereof, and one resorcinol derivative is a 4-azoaryl resorcinol of formula (II), a pharmaceutically acceptable salt and/or solvate thereof, said combination for use as an antibacterial agent, a pharmaceutical composition comprising said combination, said pharmaceutical composition for use as a medicament, and said pharmaceutical composition for use in the treatment of bacterial or infectious diseases, in particular caused by Gram-positive bacteria.

IPC Classes  ?

• A61K 31/05 - Phenols
• A61K 31/425 - Thiazoles
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61P 31/04 - Antibacterial agents

Abstract

The disclosure notably relates to a platform (100) for intermittent computing powered by at least one energy source. The platform comprises a non-volatile memory (118). The platform comprises a microcontroller (120) configured for power management of the at least one energy source and for determining a level of available energy. The platform comprises a System-on-Chip (SoC) component comprising a reprogrammable logic (118). The reprogrammable logic comprises an application layer (202) comprising operational blocks implementing one or more applications. The reprogrammable logic comprises an intermittent computing layer (204) configured for executing intermittently the one or more applications of the application layer depending on the determined level of available energy by regularly saving and restoring information from the application layer on the non-volatile memory. Such a platform presents an improved solution of energy-independent and sustainable by design system capable of performing complex processing.

IPC Classes  ?

• G06F 1/32 - Means for saving power
• G06F 1/3206 - Monitoring of events, devices or parameters that trigger a change in power modality
• G06F 1/3212 - Monitoring battery levels, e.g. power saving mode being initiated when battery voltage goes below a certain level
• G06F 1/3234 - Power saving characterised by the action undertaken
• G06F 1/324 - Power saving characterised by the action undertaken by lowering clock frequency
• G06F 1/3246 - Power saving characterised by the action undertaken by software initiated power-off
• G06F 1/3287 - Power saving characterised by the action undertaken by switching off individual functional units in the computer system
• G06F 1/329 - Power saving characterised by the action undertaken by task scheduling

Abstract

Hepcidin is an hyposideremic hormone made primarily by the liver. To address the role of hepcidin made specifically by the intestine in lowering serum iron, the inventors generated transgenic mice overexpressing the peptide specifically in this tissue. These mice exhibit, at one month of age, a severe hyposideremia, along with decreased haematological indices and hair loss. Mechanistically, they showed that intestinal hepcidin made by the transgenic mice had no effect on intestinal ferroportin, but, in contrast, induced a striking down-regulation of Divalent Metal Transporter 1 (DMT1) protein at the apical side of the enterocyte. Intestinal hepcidin can be produced in the apical side suggesting the direct role of apical hepcidin on DMT1. To confirm the therapeutic capacity of hepcidin on regulation of DMT1, the inventors developed probiotics (engineered recombinant lactic acid bacteria), capable of delivering hepcidin directly into the lumen of the intestine. They orally administrated daily these probiotics in hemochromatosis mice model, after 28 days of treatments they observe a decrease of iron overload. Thus, the present invention relates to a method for preventing or treating an iron overload associated disease in a subject in need thereof, comprising administering locally in the gut of the subject hepcidin.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Disclosed is a metal part (100) comprising a surface (112) with low hydrogen permeability. Also disclosed is a method for structuring such a part (100) by femtosecond laser irradiation.

IPC Classes  ?

• C22F 3/00 - Changing the physical structure of non-ferrous metals or alloys by special physical methods, e.g. treatment with neutrons
• B23K 26/0622 - Shaping the laser beam, e.g. by masks or multi-focusing by direct control of the laser beam by shaping pulses
• B23K 26/352 - Working by laser beam, e.g. welding, cutting or boring for surface treatment
• C21D 10/00 - Modifying the physical properties by methods other than heat treatment or deformation

Abstract

nn(x, y, z) in said plurality of regions of interest (R1, R2, R3) by processing complex modulus and phase images originating from a device (20) for magnetic resonance imaging (MRI). This method further comprises real-time processing of the thermal images, taking into account a set of planning parameters, in order to output set values for regulating the power and/or the duration of energy emission of all or part of said laser beams which are applied to one or more of the regions of interest (R1, R2, R3).

IPC Classes  ?

• A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser

Abstract

The present invention relates to molecules that have both thermally activated delayed fluorescence (TADF) and circularly polarized luminescence (CPL) properties. The invention also relates to the use of such molecules as a photocatalyst or as a dopant, in particular in the emitting layers of light-emitting diodes (OLEDs), and also to light-emitting devices or light-emitting diodes (OLEDs) comprising such compounds.

IPC Classes  ?

• C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
• C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
• H10K 50/80 - Constructional details
• H10K 85/60 - Organic compounds having low molecular weight

Abstract

ortho44 solution or human and rat microsomes. The present invention relates to astatoaryl compounds, a method for synthesizing astatoaryl compounds comprising the reaction of an aryl compound carrying a leaving group with astatine. The invention also concerns a method of synthesizing an astatolabelled biomolecule and/or vector using said astatoraryl compound.

IPC Classes  ?

• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07F 13/00 - Compounds containing elements of Groups 7 or 17 of the Periodic Table
• A61P 35/00 - Antineoplastic agents
• C07C 29/147 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen-containing functional group of C=O containing groups, e.g. —COOH of carboxylic acids or derivatives thereof
• C07C 29/62 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by introduction of halogenPreparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by substitution of halogen atoms by other halogen atoms
• C07C 33/46 - Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic part
• C07C 41/30 - Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
• C07C 43/23 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
• C07C 51/16 - Preparation of carboxylic acids or their salts, halides, or anhydrides by oxidation
• C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
• C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
• C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
• C07C 309/30 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
• C07C 63/70 - Monocarboxylic acids
• C07C 63/68 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings containing halogen
• C07C 69/76 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring
• C07C 69/157 - Acetic acid esters of monohydroxylic compounds of unsaturated alcohols containing six-membered aromatic rings
• C07C 69/68 - Lactic acid esters
• C07C 69/63 - Halogen-containing esters of saturated acids
• C07C 233/65 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals

Abstract

The present disclosure pertains to a combination of specific benzene sulfonamide thiazole compounds with an anticancer treatment for use in the treatment of cancer in a patient in need thereof. Using several cancer cell models, the present inventors have shown that a combined therapy using specific benzene sulfonamide thiazole compounds and an anticancer treatment such as an 5 immunotherapeutic agent, a chemotherapeutic agent or targeted therapies allows specifically triggering immune cell death markers, thereby potentializing the effects of each compound alone.

IPC Classes  ?

• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61P 33/00 - Antiparasitic agents

Abstract

The invention relates to a device (1) designed to be provided on a passenger compartment element, the device (1) comprising a mounting support (2) for allowing the device (1) to be mounted on the passenger compartment element, the device (1) comprising a central portion (3) which is movable around the support (2) between two separate equilibrium positions in which the central portion (3) is in stable equilibrium, the central portion (3) being extended by a plurality of lateral extensions (4a, 4b, 4c, 4d) connecting the central portion (3) to the support (2) and each being designed, on the one hand, to guide the movement, initiated by a user of the device, of the central portion (3) between its two equilibrium positions by elastic deformation of the lateral extension (4a, 4b, 4c, 4d) and, on the other hand, to keep the central portion (3) in the equilibrium position into which the central portion (3) is brought, and each lateral extension (4a, 4b, 4c, 4d) being integral with the central portion (3).

IPC Classes  ?

• B60N 3/00 - Arrangements or adaptations of other passenger fittings, not otherwise provided for
• B60R 7/04 - Stowing or holding appliances inside of vehicle primarily intended for personal property smaller than suit-cases, e.g. travelling articles, or maps in driver or passenger space

Abstract

The present invention relates to a power battery comprising a plurality of elementary energy storage modules connected in series in at least one current line so as to form a multilevel inverter distributed within the battery, wherein the plurality of elementary modules comprises at least one first elementary module in which the electrochemical cells (21) of the cluster (CL1) are interconnected according to a first interconnection configuration that determines a first cluster voltage level (VCL1), and a second elementary module in which the electrochemical cells (24) of the cluster (CL4) are interconnected according to a second interconnection configuration that determines a second cluster voltage level (VCL4), wherein the second cluster voltage level (VCL4) is the maximum cluster voltage of the battery and the first cluster voltage level (VCL1) is strictly lower than the second cluster voltage level (VCL4).

IPC Classes  ?

• H02J 7/00 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
• B60L 58/19 - Switching between serial connection and parallel connection of battery modules
• H02J 7/36 - Arrangements using end-cell switching
• H02M 7/483 - Converters with outputs that each can have more than two voltage levels
• B60L 58/21 - Methods or circuit arrangements for monitoring or controlling batteries or fuel cells, specially adapted for electric vehicles for monitoring or controlling batteries of two or more battery modules having the same nominal voltage
• H02M 1/00 - Details of apparatus for conversion
• H02M 1/10 - Arrangements incorporating converting means for enabling loads to be operated at will from different kinds of power supplies, e.g. from AC or DC
• H02M 7/49 - Combination of the output voltage waveforms of a plurality of converters

Abstract

The invention relates to a component (1) comprising a planar transformer (3) formed on a PCB (2) by the interleaving of a primary winding (33) and a secondary winding (34) in a winding window formed by a first magnetic core (31, 32). It also comprises a planar inductor (4) formed by the extension of at least one of the windings by two connection tracks (340) forming connection terminals (53, 54) and by the arrangement of a second magnetic core (41, 42) around a portion (44) of each of the two connection tracks. Preferably, the planar inductor (4) is formed at the terminals of the low-voltage winding. The connection tracks (340) are formed on the same PCB to obtain a one-piece planar component, or formed on a separate PCB to obtain a rigid-flex component, wherein the flexible portion consists of a portion (60) of the connection tracks (340).

IPC Classes  ?

• H01F 27/28 - CoilsWindingsConductive connections
• H01F 27/33 - Arrangements for noise damping
• H01F 27/38 - Auxiliary core membersAuxiliary coils or windings

Abstract

According to one aspect, the invention relates to a portable device (1) for detecting a laser beam, the portable detection device comprising: - a support portion (10) comprising: a1) a device for autonomously powering the portable detection device, and b1) a holding element (12) for holding the portable detection device, - a detection portion (20) for detecting the laser beam, comprising: a2) an optical system (22) suitable for forming an image comprising the laser beam, the laser beam having a wavelength of less than 1.6 micrometres, b2) at least one sensor (24) suitable for detecting the laser beam on the image formed by the optical system and for providing an output signal associated with the detected laser beam, and - a computer configured to digitally process the output signal generated by the sensor so as to generate a digital image of the detected laser beam.

IPC Classes  ?

• G01J 1/02 - Photometry, e.g. photographic exposure meter Details
• G01J 1/04 - Optical or mechanical part
• G01J 1/42 - Photometry, e.g. photographic exposure meter using electric radiation detectors

Abstract

The present invention relates to combination of (i) a methionine-depleting composition, of (ii) one or more methionine synthase inhibitors and of (iii) optionally one or more further agent selected from a chemotherapeutic agent, a radiotherapeutic agent or an immunotherapeutic agent against cancer, for its use for treating a cancer, especially in cancers involving the presence of methionine-independent cancer cells

IPC Classes  ?

• A61K 38/51 - Lyases (4)
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The disclosure relates to an aqueous composition, having a Newtonian viscosity between 0.5 Pa.s and 1000 Pa.s, comprising at least one statistical polysaccharide B, having a weight-average molar mass of between 100 kDa and 1000 kDa, of formula I: and optionally a chitosan A, said statistical polysaccharide B being in a mass concentration CB, said chitosan A being in a mass concentration CA, the sum of CB plus CA being of at least 10 g.L-1. The disclosure also concerns the aqueous composition mentioned above for its use in the treatment of complex wounds, such as wounds related to diabetes, burns and wounds containing one or more metals, and to a to a wound dressing comprising said aqueous composition.

IPC Classes  ?

• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

The invention relates to a method for preparing a mixture of linear alkanes of natural origin, preferably of plant origin, comprising the steps of: i) metathesis of at least one terminal linear olefin having from 5 to 24 carbon atoms, derived from at least one fatty acid or fatty acid ester of natural origin, preferably of plant origin, in the presence of a non-isomerising olefin metathesis catalyst, whereby a first mixture of internal olefins (I) is obtained; ii) isomerising metathesis of the mixture of internal olefins (I) obtained in step i) in the presence of a catalyst or a mixture of catalysts, whereby a second mixture of internal olefins (II) is obtained; and iii) hydrogenation of the mixture of internal olefins (II) in the presence of a catalyst, whereby a mixture (III) of linear alkanes of natural origin is obtained.

IPC Classes  ?

• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
• C07C 5/03 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by hydrogenation of non-aromatic carbon-to-carbon double bonds
• C07C 5/25 - Migration of carbon-to-carbon double bonds
• C07C 6/04 - Metathesis reactions at an unsaturated carbon-to-carbon bond at a carbon-to-carbon double bond

Abstract

in vivoin vivo fluorescence-lifetime imaging. The compounds have the general formula (I) below:

IPC Classes  ?

• C09B 57/00 - Other synthetic dyes of known constitution
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61K 49/00 - Preparations for testing in vivo
• C07F 5/02 - Boron compounds
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• G01N 33/533 - Production of labelled immunochemicals with fluorescent label
• C09B 23/04 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups one CH group, e.g. cyanines, isocyanines, pseudocyanines
• C09B 69/10 - Polymeric dyesReaction products of dyes with monomers or with macromolecular compounds
• C09B 55/00 - Azomethine dyes

Abstract

Myotonic Dystrophy type 1 (DM1) is an inherited disease characterized by multi-systemic symptoms, particularly in skeletal muscles (progressive weakness and atrophy, myotonia). The inventors screened 7 500 bioactive compounds for their ability to improve the myogenic fusion and reduce the molecular hallmarks of DM1 skeletal muscle cells. The inventors found that five compounds, all inhibiting HDAC6, a cytoplasmic histone deacetylase, were effective at the micromolar range in normalizing the myogenic fusion, reducing the number of nuclear foci of mutant DMPK mRNA, decreasing the expression level of DMPK mRNA, restoring the splicing of several genes, and increasing the acetylation of SMAD3, a transcription factor involved in muscle development. The effects of HDAC6 inhibitors were observed both in immortalized and hiPSC-derived skeletal muscle cells from DM1 patients, and in different stages of differentiation. Thus, the present invention relates to the use of selective HDAC6 inhibitors for the treatment of DM1.

IPC Classes  ?

• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/42 - Oxazoles
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

A micro-capacitor comprising: - a structured support comprising a substrate and micro-pillars disposed on one face of the substrate, - a first electrode disposed on the structured support, - a second electrode, and - an insulating material disposed between the first and second electrodes.

IPC Classes  ?

• H01G 4/008 - Selection of materials
• H01G 4/012 - Form of non-self-supporting electrodes
• H01G 4/33 - Thin- or thick-film capacitors
• H10D 1/68 - Capacitors having no potential barriers

Abstract

A micro-battery comprising: - a structured support comprising a substrate including micro-pillars disposed on one face of the substrate, each micro-pillar having a free surface, and nano-wires disposed on the free surface of at least a portion of the micro-pillars; - a first current collector disposed on the structured support and a second current collector; - a first electrode disposed on the first current collector, and a second electrode, the first and second electrodes being disposed between the first and second current collectors; and - an electrolyte disposed between the first and second electrodes.

IPC Classes  ?

• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• H01M 4/70 - Carriers or collectors characterised by shape or form
• H01M 10/04 - Construction or manufacture in general
• H01M 10/052 - Li-accumulators
• H01M 10/0562 - Solid materials
• H01M 6/40 - Printed batteries

Abstract

aaaaaaa filtered images.

IPC Classes  ?

• A61B 8/08 - Clinical applications
• G01S 15/89 - Sonar systems specially adapted for specific applications for mapping or imaging
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves

Abstract

The invention relates to a computer-implemented method (100) for generating patient- specific templates of aortic leaflets comprising: - generating (104) a 3D model from digital images (102) of a native aortic root and aortic leaflets of a patient; - generating (106) 3D neo-leaflets models by simulating in silico aortic leaflet neocuspidization from the 3D model with parameters of developable coaptation surfaces and of non-developable load-bearing surfaces of aortic leaflets; - realizing (108) a 2D surface flattening of the coaptation surfaces of the 3D neo- leaflets models; - realizing (110) a 2D surface flattening of the load-bearing surfaces of the 3D neo- leaflets models; - merging (112) a 2D coaptation surface with a 2D load-bearing surface for each neo- leaflet model; and - generating (114) a patient-specific template for each aortic leaflet.

IPC Classes  ?

• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G06T 13/40 - 3D [Three Dimensional] animation of characters, e.g. humans, animals or virtual beings

Abstract

Circadian rhythms control the diurnal nature of many physiological, metabolic and immune processes. The inventors hypothesized that age-related impairments in circadian rhythms are associated with high susceptibility to bacterial respiratory tract infections. The diurnal control of Streptococcus pneumoniae infection is impaired in elderly mice. A lung circadian transcriptome analysis revealed that aging alters the daily oscillations in the expression of a specific set of genes and that some pathways that are rhythmic in young-adult mice are nonrhythmic or time-shifted in elderly mice. In particular, the circadian expression of the clock components Rev-erb-α, and Rev-erb-β to a lesser extent, altogether with apelin/apelin receptor were altered in elderly mice compared to young mice. In young mice, the inventors discovered that novel interaction between Rev-erb and the apelinergic axis controls host defenses against S. pneumoniae via alveolar macrophages. Pharmacological repression of Rev-erb-α and/or Rev- erb-β in elderly mice resulted in greater resistance to pneumococcal infection. Thus, the present invention relates to the use of Rev-erb antagonists for the treatment of lung infections.

IPC Classes  ?

• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 31/04 - Antibacterial agents
• A61P 31/10 - Antimycotics
• A61P 31/12 - Antivirals

Abstract

The present invention relates to the field of treat age-related cognitive declines. In this study, the inventors report that GPR158, which localizes at the PC, is required for OCN- dependent autophagy induction in hippocampal neurons. Consistently, the mobilization of key autophagy players by OCN in hippocampal neurons requires core PC-proteins. In aged hippocampi, neuronal PC present an abnormal morphology, correlated with a reduction of the major core ciliary proteins levels. Conversely, restoration of their levels in aged hippocampi is sufficient to improve autophagy and cognitive deficits. Lastly, they show that core PC-proteins are required to integrate the rejuvenating effects of OCN in the hippocampus, thereby ameliorating age-related cognitive deficits. Altogether, these findings demonstrate a new paradigm for the neuron/systemic milieu communication and significantly advance our understanding of the regulatory mechanism mediating the rejuvenating effects of the pro-youth blood factor, OCN, in hippocampal neurons. This study also provides the foundation for novel therapeutic strategies to treat age-related cognitive decline, as well as neurological deficits in ciliopathies. Thus, the present invention relates to an activator of the primary cilia (PC) for use in the restoration and/or improvement of cognitive functions in a subject in need thereof.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 31/365 - Lactones
• A61P 25/00 - Drugs for disorders of the nervous system
• C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The present invention relates to an electrical system (1) comprising an electric machine (5), a power battery (2) comprising a multilevel inverter distributed within the battery and suitable for supplying power to the electric machine (5), and a diagnostic means (3) suitable for controlling a commanded short-circuit mode of the electric machine (5), wherein the battery (2) comprises at least one current line (21) comprising a plurality of energy storage devices (MCLk) connected in series, wherein each storage device (MCLk) comprises an electrochemical energy storage element (CLk) supplying a voltage and a switching circuit (COMk) comprising an H-bridge, and wherein the diagnostic means (3) is configured to control all of the switching circuits of the battery into the bypass state when the commanded short-circuit mode of the electric machine (5) is activated.

IPC Classes  ?

• B60L 3/00 - Electric devices on electrically-propelled vehicles for safety purposesMonitoring operating variables, e.g. speed, deceleration or energy consumption
• B60L 50/64 - Constructional details of batteries specially adapted for electric vehicles

Abstract

The present invention relates to the definition of a pool of antigenic sperm peptides with high species specificity for regulating populations of water vole (Arvicola terrestris scherman) using a vaccine approach.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Device for muscular and/or nervous electrostimulation This device (30) for muscular and/or nervous electrostimulation is configured to generate an adaptive electromagnetic field, comprising an electronic circuit (32) comprising a power generating unit, configured to generate a periodical electric current and a periodical voltage, at least one resistor (36) and at least one inductor (38) connected in series and powered by said power generating unit, the at least one inductor (38) generating a magnetic field, measured as a magnetic induction signal comprising a train of periodic magnetic induction pulses, each magnetic induction pulse having an intensity of less than 10 micro Tesla, a frequency lower than 1000 Hertz and a pulse width lower than 100 milliseconds, and comprising a main peak and a plurality of secondary peaks corresponding to secondary oscillations, the device further comprising a filtering module (40) configured to attenuate or suppress at least part of the secondary oscillations of each magnetic induction pulse.

IPC Classes  ?

• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
• A61N 2/00 - Magnetotherapy

Abstract

1212jc122) configured to generate and/or detect, in correspondence with the ferromagnetic element of said transducer, an electromagnetic mode (MEL) suitable for exciting or being able to be generated by said magnetic oscillation mode of the ferromagnetic element.

IPC Classes  ?

• G01N 29/24 - Probes
• H01F 1/00 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties

Abstract

Here, the inventors use genomics to discover a new family of lanthipeptides from Actinobacteria dedicated to anti-phage defense. They demonstrate that a specific family of metabolic pathways that produce unknown class I lanthipeptides are encoded near known anti-phage defense systems or within mobile genetic elements, indicating their anti-phage function. Furthermore, the inventors show that the heterologous expression of these pathways in Streptomyces albus (a model strain of Actinobacteria) confers anti-phage defense. The experimental results show that different lanthipeptides of this family confer a selective protection against phages, without compromising the cell viability. The inventors also have identified a specific regulatory system that controls the expression of "defensive lanthipeptides" in Actinobacteria and use this to demonstrate their anti-phage function in a native strain. Finally, the inventors explore the anti-phage mechanism of action of these compounds. Thus the present invention relates to a new class of anti-phage natural peptides.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 7/54 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring

Abstract

A structured support for an energy storage micro-device, comprising: - a substrate; - micro-pillars disposed on one face of the substrate, each micro-pillar having a free surface; - nano-wires, said nano-wires being disposed on the free surface of at least a portion of the micro-pillars, and said face of the substrate being devoid of nano-wires.

IPC Classes  ?

• H01G 11/24 - Electrodes characterised by structural features of the materials making up or comprised in the electrodes, e.g. form, surface area or porosityElectrodes characterised by the structural features of powders or particles used therefor
• H01G 4/012 - Form of non-self-supporting electrodes
• H01G 4/008 - Selection of materials
• H01G 11/26 - Electrodes characterised by their structure, e.g. multi-layered, porosity or surface features
• H01G 11/50 - Electrodes characterised by their material specially adapted for lithium-ion capacitors, e.g. for lithium-doping or for intercalation
• H01G 11/68 - Current collectors characterised by their material
• H01G 11/70 - Current collectors characterised by their structure
• H01G 4/33 - Thin- or thick-film capacitors
• H01M 4/04 - Processes of manufacture in general
• H01M 4/02 - Electrodes composed of, or comprising, active material
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures
• H10D 1/68 - Capacitors having no potential barriers

Abstract

The invention relates to a laser welding method comprising the following steps: 1) placing (62) a first face of a first semiconductor part directly against a second face of a second semiconductor part in order to form a joining plane; then 2) producing welding spots in the joining plane using laser pulses, wherein the reflection of a laser pulse by a defect in the joining plane is minimised: a) by emitting the laser pulse in a wavelength range in which this reflection is minimised; b) by modifying the thickness of the defect in order to obtain a thickness that minimises the reflection of the laser pulse; or c) by treating (122) the first and/or the second face in order to form therein cavities having different depths, which cavities are uniformly distributed over this face.

IPC Classes  ?

• B23K 26/06 - Shaping the laser beam, e.g. by masks or multi-focusing
• B23K 26/0622 - Shaping the laser beam, e.g. by masks or multi-focusing by direct control of the laser beam by shaping pulses
• B23K 26/22 - Spot welding
• B23K 26/324 - Bonding taking account of the properties of the material involved involving non-metallic parts
• B23K 26/57 - Working by transmitting the laser beam through or within the workpiece the laser beam entering a face of the workpiece from which it is transmitted through the workpiece material to work on a different workpiece face, e.g. for effecting removal, fusion splicing, modifying or reforming
• B23K 26/60 - Preliminary treatment
• B23K 26/352 - Working by laser beam, e.g. welding, cutting or boring for surface treatment
• B23K 26/244 - Overlap seam welding
• B23K 101/40 - Semiconductor devices
• B23K 103/00 - Materials to be soldered, welded or cut

Abstract

The present invention relates to a method for synthesising a final composition comprising at least one polyol ester and a carboxylic acid, which method implements an exothermic acylation reaction from an initial immiscible mixture comprising at least two (immiscible) liquid starting reagents which are a polyol and an acid anhydride, characterised in that said method is carried out in a continuous flow in a mechanical mixer comprising at least one mixing chamber, the method comprising the following successive steps: (A) introducing, at ambient temperature, the at least two starting reagents into the mixer in order to form the initial mixture; (B) stirring the initial mixture in the mechanical mixer for a residence time of less than or equal to 1 hour; (C) recovering said final composition at the outlet of the mixer.

IPC Classes  ?

• C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
• C07C 69/18 - Acetic acid esters of trihydroxylic compounds
• C07C 69/21 - Acetic acid esters of hydroxy compounds with more than three hydroxy groups
• C07C 69/30 - Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds

Abstract

The present invention relates to mineral fibers grafted with amine functions, characterized in that said fibers have a surface roughness defined by a root mean square deviation Rq greater than or equal to 0.70 nm, and in that they have a degree of grafting of at least 85 pmol of amine functions per mm2, to the use of said fibers as reinforcing material, to a composite comprising at least one organic material and such fibers, and to a process for producing said fibers, characterized in that it comprises at least one step of depositing, by plasma-enhanced chemical vapor deposition (PE-CVD), a layer of at least one precursor chosen from an aminosilane and a mixture of a primary amine and a source of silica on mineral fibers.

IPC Classes  ?

• C03C 25/223 - Deposition from the vapour phase by chemical vapour deposition or pyrolysis
• C03C 25/40 - Organo-silicon compounds
• C03C 25/6293 - Plasma or corona discharge
• D06M 11/01 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with hydrogen, water or heavy waterTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with hydrides of metals or complexes thereofTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereofSuch treatment combined with mechanical treatment, e.g. mercerising with boranes, diboranes, silanes, disilanes, phosphines, diphosphines, stibines, distibines, arsines or diarsines or complexes thereof
• D06M 13/328 - Amines the amino group being bound to an acyclic or cycloaliphatic carbon atom
• D06M 13/513 - Compounds with at least one carbon-metal or carbon-boron, carbon-silicon, carbon-selenium, or carbon-tellurium bond with at least one carbon-silicon bond

Abstract

The present invention provides fusion molecules comprising the extracellular domain of CSF-1R which contains a specific single amino acid mutation. Such fusion molecules are capable of efficiently binding both CSF-1 and IL-34. The present invention also provides the use of such fusion molecules, or pharmaceutical compositions thereof, as therapeutic agents, in particular in the treatment of cancers, neurodegenerative diseases, autoimmune diseases, and allergic diseases, or in the prevention or inhibition of transplant rejection.

IPC Classes  ?

• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

The invention relates to the field of Bipolar Disorder. In a recent study, the inventors performed the first genome-wide analysis of DNA methylation profiles among individuals with BD type I assessed for their response to long-term treatment with Li and identified differentially methylated regions (DMRs) between GR and NR, selecting only methylation differences that were not impacted by co-prescribed treatments that are -by definition- more frequent in NR (Marie-Claire et al., 2020). They then used MS-HRM to validate 3 DMRs that discriminated GR from NR in an extended sample of 70 individuals with BD-I. They also showed, in an independent sample that combining a few clinical variables with the three DMRs improved the performance of these MS-HRM-based biomarkers to discriminate groups (Marie-Claire et al., 2023). In the present study, they improved the performance of the combination of MS-HRM- based biomarkers and clinical predictors to discriminate individuals that benefited from Li treatment (GR and PaR) from those who did not (NR) in a retrospective sample. Thus, the present invention relates to a method for predicting whether a patient achieves a response with a treatment of Bipolar Disorder (BD) comprising determining, in a biological sample from the patient the epigenetic profile of at least 4 of the differentially methylated regions (DMRs) selected in the list consisting of DMR7291, DMR17107, DMR17978, DMR24332, DMR63769, DMR79888, DMR106540 and DMR81023.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Inventors demonstrated that an epigenetic regulator CBX3 antagonizes IFNγ signalling via directly repressing the transcription of two key interferon-stimulated immune genes, STAT1 and PD-L1. The key role of CBX3 in repressing STAT1 and PD-L1 transcription suggests that CBX3 is an important checkpoint to control immune genes' activation in response to different ligands' stimulation, such as the important immune modulator IFNγ, which placed CBX3 in a key position to keep colon immune homeostasis. This role placed also CBX3 in a key position to keep colon immune homeostasis. These studies have started to reveal a new role of CBX3 in controlling the colon epithelium inflammatory response, in addition to its classical role in the formation and stabilization of heterochromatin. Particularly, low CBX3 expression is associated with better CRC patients' overall survival. Corresponding to this result, CBX3 depletion makes IFNγ-insensitive CRC cells dramatically regain IFNγ sensitivity, which significantly increases CRC cells' chemosensitivity under IFNγ stimulation. Accordingly, the invention relates to a Chromobox protein homolog 3(CBX3) inhibitor for use in the treatment of cancer in a subject in need thereof.

IPC Classes  ?

• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 38/21 - Interferons
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Abstract

The present invention relates to compounds of formula (I) and its use for photothermal therapy preferably for the treatment of cancer, for examples for the treatment of glioblastoma, prostate cancer, breast cancer and melanoma.

IPC Classes  ?

• C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
• C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a control device for an electrical machine (2), the device comprising a power management assembly (90) that comprises a power interface (9) and a power supply system (3), the power supply system (3) comprising a power converter (5), the device comprising an electronic control unit (20) configured to control the power interface (9) so as to regulate a power factor between the power converter (5) and the power interface with respect to a power factor setpoint, such that the power interface (9) supplies at least some of the reactive power consumed by the electric machine (2) so that the power management assembly (90) can exchange an apparent power strictly greater than an initial apparent power with the electric machine (2).

IPC Classes  ?

• H02P 23/26 - Power factor control [PFC]
• H02J 3/18 - Arrangements for adjusting, eliminating or compensating reactive power in networks
• H02M 7/483 - Converters with outputs that each can have more than two voltage levels
• H02M 1/00 - Details of apparatus for conversion
• H02M 1/42 - Circuits or arrangements for compensating for or adjusting power factor in converters or inverters
• H02M 7/5387 - Conversion of DC power input into AC power output without possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only, e.g. single switched pulse inverters in a bridge configuration